Stifel Financial’s Aratana Therapeutics, Inc. PETX Stock Holding History

Stifel Financial’s Portfolio PETX Stock Details PETX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-10,100	Closed	-$37K	–	3104
2019 Q1	$37K	Sell	10,100 -125,320	-93%	-$543K	﹤0.01%	2757
2018 Q4	$828K	Sell	135,420 -3,200	-2%	-$19.5K	﹤0.01%	1661
2018 Q3	$811K	Buy	138,620 +7,090	+5%	+$35.4K	﹤0.01%	1812
2018 Q2	$560K	Buy	131,530 +114,480	+671%	+$577K	﹤0.01%	1970
2018 Q1	$75K	Buy	17,050 +2,600	+18%	+$11.6K	﹤0.01%	2590
2017 Q4	$76K	Buy	14,450 +150	+1%	+$918	﹤0.01%	2568
2017 Q3	$87K	Hold	14,300	–	–	﹤0.01%	2483
2017 Q2	$103K	Hold	14,300	–	–	﹤0.01%	2456
2017 Q1	$76K	Buy	+14,300	New	+$96.6K	﹤0.01%	2452

Other funds holding PETX

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return

WIC

Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return

Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

GAI

General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OAC

OMERS Administration Corp Toronto, Ontario, Canada $15.6B AUM 24.73% 1-Year Est. Return

Stifel Financial's PETX Position: Q2 2019 in Review

Stifel Financial sold out of Aratana Therapeutics, Inc. (PETX) in Q2 2019, closing a stake of 10,100 shares — an estimated $37K sold.

Stifel Financial first reported a position in PETX in Q1 2017 and held it in 9 quarters. The position peaked at $828K in Q4 2018. 103 funds tracked by Wall St. Rank hold PETX as of Q2 2019.

Stifel Financial reported no remaining Aratana Therapeutics, Inc. position as of Q2 2019 after selling out during the quarter.
Stifel Financial sold 10,100 Aratana Therapeutics, Inc. shares in Q2 2019, an estimated $37K.
Stifel Financial first reported a position in Aratana Therapeutics, Inc. in Q1 2017 and held it in 9 quarters.
Stifel Financial's Aratana Therapeutics, Inc. position peaked at $828K in Q4 2018.
103 funds tracked by Wall St. Rank held Aratana Therapeutics, Inc. as of Q2 2019.

Based on Stifel Financial's 13F filing for Q2 2019, filed 14 Aug 2019.